Citadel Advisors
OKUR

Citadel Advisors’s OnKure Therapeutics OKUR Stock Holding History

Citadel Advisors’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-310
Closed -$5.15K – 15629
2024
Q1 		$5.15K Sell
310
-2,290
-88% -$37.8K ﹤0.01% 13763
2023
Q4 		$41.6K Buy
2,600
+2,580
+12,900% +$161K ﹤0.01% 11980
2023
Q3 		$1.52K Buy
+20
New +$1.36K ﹤0.01% 13850

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's OKUR Position: Q2 2026 in Review

Citadel Advisors increased its OnKure Therapeutics (OKUR) stake by 3,058% in Q2 2026, buying an estimated $4.93M and bringing the position to 1,187,047 shares worth $5.41M. The position accounts for ﹤0.01% of the portfolio, ranked #4581.

Citadel Advisors first reported a position in OKUR in Q2 2022 and has held it in 15 quarters since. The position peaked at $8.78M in Q4 2024. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Citadel Advisors held 1,187,047 shares of OnKure Therapeutics worth $5.41M as of Q2 2026.
  • Citadel Advisors bought 1,149,460 OnKure Therapeutics shares in Q2 2026, an estimated $4.93M.
  • OnKure Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #4581 holding.
  • Citadel Advisors first reported a position in OnKure Therapeutics in Q2 2022 and has held it in 15 quarters since.
  • Citadel Advisors's OnKure Therapeutics position peaked at $8.78M in Q4 2024.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.